2026/03/31 更新

写真a

オカモト　カズヒロ
岡本　和浩
Okamoto Kazuhiro
所属
学術研究院医療開発領域 助教
職名
助教
外部リンク
 

論文

  • Leucine-rich Repeat-containing 15 as a Potential Marker and Therapeutic Target in Cervical Cancer. 国際誌

    Thi Hai Ly Dao, Keiichiro Nakamura, Kazuhiro Okamoto, Thuy Ha Vu, Eriko Eto, Hisashi Masuyama

    Anticancer research   45 ( 12 )   5409 - 5421   2025年12月

    　詳細を見る

    記述言語：英語   掲載種別：研究論文（学術雑誌）  

    BACKGROUND/AIM: Leucine-rich repeat-containing 15 (LRRC15) is a recently identified cancer-associated fibroblast (CAF) marker found in various types of cancer. However, its functional role and clinical significance in cervical cancer (CC) remain unclear. MATERIALS AND METHODS: We analyzed LRRC15 expression in 20 normal cervical (NC) tissue samples and 87 CC tissue samples using RT-qPCR. Correlations between LRRC15 expression and clinicopathological parameters and prognosis in CC patients were evaluated. The biological functions of LRRC15 and its effects were investigated in CC cell lines with and without human papillomavirus (HPV) infection. RESULTS: LRRC15 expression was significantly associated with lympho-vascular space (LVS) involvement in patients with CC (p<0.001). Patients with high LRRC15 expression had significantly poorer progression-free survival outcomes than those with low LRRC15 expression (p=0.014). LRRC15 knockdown suppressed WNT and focal adhesion kinase (FAK) signaling, leading to increased Caspase3/7 expression and, consequently, enhanced apoptosis in CC cells, regardless of HPV infection. CONCLUSION: LRRC15 expression is a marker of poorer prognosis in patients with CC, suggesting that LRRC15 represents a potential therapeutic strategy for CC.

    DOI： 10.21873/anticanres.17877

    PubMed

    researchmap

  • CD63 as a potential biomarker for patients with ovarian cancer. 国際誌

    Keiichiro Nakamura, Naoyuki Ida, Akira Hirasawa, Kazuhiro Okamoto, Thuy Ha Vu, Dao Thi Hai Ly, Hisashi Masuyama

    European journal of obstetrics, gynecology, and reproductive biology   306   87 - 93   2025年3月

    　詳細を見る

    記述言語：英語   掲載種別：研究論文（学術雑誌）  

    INTRODUCTION: Exosomes play an important role in regulating physiological processes and mediating the systemic dissemination of various types of cancer. We investigated the association of exosomal tetraspanins CD9, CD63, and CD81 in patients with ovarian cancer (OC). MATERIAL AND METHODS: We measured the plasma tetraspanins CD9, CD63, and CD81 by enzyme-linked immunosorbent assay in 91 patients who underwent treatment for OC between April 2018 and March 2024. Additionally, we analyzed clinical pathologic factors, chemotherapy response, and prognosis. RESULTS: In terms of stages, CD63 expression was significantly higher in patients with stage IV compared to those with stage I OC (p = 0.003). In terms of histological type, CD63 expression was significantly higher in high-grade serous carcinoma (HGSC) than in clear cell carcinoma (CCC) with OC (p = 0.009). Furthermore, CD63 levels were significantly higher in advanced-stage, HGSC than in patients with early-stage, non-HGSC and early-stage, HGSC OC (p = 0.045 and p = 0.002, respectively). In the Neoadjuvant chemotherapy (NAC) of 12 patients with OC assessed as having either a partial response (PR) or complete response (CR), CD63 was significantly decreased (p = 0.043), whereas perforin was significantly increased (p = 0.001). In the NAC of 16 patients with OC, CD63 of the response rate to chemotherapy tended to differ between the progressive disease (PD) and PR/CR groups (p = 0.056). A moderate inverse correlation was observed between CD63 and perforin levels (R = 0.638, R2 = 0.428, p = 0.008). CONCLUSIONS: CD63 could be a potential biomarker for all types of OC patients.

    DOI： 10.1016/j.ejogrb.2025.01.011

    PubMed

    researchmap

  • ADAR1 could be a potential diagnostic target for intrauterine infection patients. 国際誌

    Keiichiro Nakamura, Kunitoshi Shigeyasu, Thuy Ha Vu, Jota Maki, Kazuhiro Okamoto, Hisashi Masuyama

    Scientific reports   14 ( 1 )   29419 - 29419   2024年11月

    　詳細を見る

    記述言語：英語   掲載種別：研究論文（学術雑誌）  

    Intrauterine infection (IUI) is mainly an ascending infection in which vaginal and cervical pathogens ascend to the uterus and can affect the fetus. Until now, there is still no effective diagnostic biomarker for IUI, such as chorioamnionitis (CAM) and funisitis (FUN). Deoxyribonucleic acid (DNA)/Ribonucleic acid (RNA) editing molecules such as apolipoprotein-B mRNA-editing complex (APOBEC) 3 families and Adenosine deaminase family acting on RNA (ADAR)1 were examined in chorioamniotic membranes and umbilical cord of 83 patient samples. Furthermore, Ureaplasma parvum induced ADAR1 was investigated in human HTR-8/SVneo EVT cell line. ADAR1 had a significantly higher area under the curve (AUC) (0.721 and 0.745) than other APOBEC3s or cytokines in CAM and FUN patients. In vitro, ureaplasma parvum was demonstrated to activate ADAR1 (p = 0.025) and reduce RIG-I, IRF3, IFN-[Formula: see text], and IFN-β expression in EVT cell line (p = 0.005, p = 0.010, p < 0.001, and p = 0.018, respectively). High expression of ADAR1 was strongly associated with CAM and FUN patients (multivariate analyses; p = 0.035 and p = 0.002). ADAR1 could be a potential diagnostic target for IUI, such as CAM and FUN patients.

    DOI： 10.1038/s41598-024-81097-4

    PubMed

    researchmap

  • Apolipoprotein-B mRNA-editing complex 3B could be a new potential therapeutic target in endometriosis. 国際誌

    Thuy Ha Vu, Keiichiro Nakamura, Kunitoshi Shigeyasu, Chiaki Kashino, Kazuhiro Okamoto, Kotaro Kubo, Yasuhiko Kamada, Hisashi Masuyama

    Scientific reports   14 ( 1 )   24968 - 24968   2024年10月

    　詳細を見る

    記述言語：英語   掲載種別：研究論文（学術雑誌）  

    This study investigated the correlation of Apolipoprotein-B mRNA-editing complex 3B (APOBEC3B) expression with hypoxia inducible factor 1α (HIF-1α), Kirsten rat sarcoma virus (KRAS) and phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA) in endometriosis patients, and the inhibitory effects of APOBEC3B knockdown in a human endometriotic cell line. Here, APOBEC3B, HIF-1α, KRAS, and PIK3CA were examined in patients with and without endometriosis using reverse transcription polymerase chain reaction (RT-PCR). The apoptosis, cell proliferation, invasion, migration, and biological function of APOBEC3B knockdown were explored in 12Z immortalized human endometriotic cell line. We observed APOBEC3B, HIF-1α, KRAS and PIK3CA expressions were significantly higher in endometriosis patients (p < 0.001, p < 0.001, p = 0.029, p = 0.001). Knockdown of APOBEC3B increased apoptosis, which was 28.03% and 22.27% higher than in mock and control siRNA samples, respectively. APOBEC3B knockdown also decreased PIK3CA expression and increased Caspase 8 expression, suggesting a potential role in the regulation of apoptosis. Furthermore, knockdown of APOBEC3B significantly inhibited cell proliferation, invasion, and migration compared to mock and control siRNA. (Cell proliferation: mock: p < 0.001 and control siRNA: p = 0.049. Cell invasion: mock: p < 0.001 and control siRNA: p = 0.029. Cell migration: mock: p = 0.004, and control siRNA: p = 0.014). In conclusion, this study suggests that APOBEC3B may be a new potential therapeutic target for endometriosis.

    DOI： 10.1038/s41598-024-76589-2

    PubMed

    researchmap

  • Not taking sick leave for gynecologic cancer treatment is negatively associated with returning to the same workplace. 国際誌

    Keiichiro Nakamura, Hirofumi Matsuoka, Kotaro Kubo, Shinsuke Shirakawa, Naoyuki Ida, Junko Haraga, Chikako Ogawa, Kazuhiro Okamoto, Shoji Nagao, Hisashi Masuyama

    Japanese journal of clinical oncology   54 ( 3 )   292 - 296   2024年3月

    　詳細を見る

    記述言語：英語   掲載種別：研究論文（学術雑誌）  

    BACKGROUND: Gynecologic cancers are one of the most common types of malignancies in working-age women. We aimed to determine the factors that impede women from returning to the same workplace after treatment for such cancers. METHODS: A questionnaire-based survey was conducted on 194 women who underwent treatment for gynecologic cancer at the Okayama University (≥1 year after cancer treatment and <65 years of age). We performed a logistic regression analysis to determine the relationship between returning to the same workplace and not taking sick leave. RESULTS: The median age at diagnosis was 49.0 years, and the median time from cancer treatment to questionnaire completion was 3.8 years. Not returning to the same workplace was positively associated with not being regularly employed (P = 0.018), short work time per day (P = 0.023), low personal income (P = 0.004), not taking sick leave (P < 0.001), advanced cancer stage (P = 0.018) and long treatment time (P = 0.032). Interestingly, not taking sick leave was strongly associated with not returning to the same workplace in the multivariable analysis (P < 0.001). CONCLUSIONS: Not taking sick leave likely was negatively associated with returning to the same workplace after the treatment for gynecologic cancer. Therefore, we suggest that steps be taken to formally introduce a sick leave system over and above the paid leave system in Japan.

    DOI： 10.1093/jjco/hyad159

    PubMed

    researchmap

  • Pure abscopal effect in a patient with advanced uterine carcinosarcoma. 国際誌

    Kazuhiro Okamoto, Kotaro Yoshio, Shinsuke Shirakawa, Kyohei Irie, Naoyuki Ida, Hirofumi Matsuoka, Junko Haraga, Chikako Ogawa, Keiichiro Nakamura, Shoji Nagao, Hisashi Masuyama

    Radiology case reports   18 ( 7 )   2447 - 2451   2023年7月

    　詳細を見る

    記述言語：英語   掲載種別：研究論文（学術雑誌）  

    The abscopal effect is a rare phenomenon, in which tumor shrinkage in the nonirradiated metastatic region is observed after radiotherapy. Certainly, this response is sometimes reported with the combined use of immune-checkpoint inhibitors, but a pure abscopal effect is extremely rare, especially in endometrial cancer. We present the case of a 79-year-old woman with an advanced endometrial carcinosarcoma. She was treated with surgical reduction of the primary lesion, followed by radiotherapy of the metastatic regional lymph nodes. Distant metastases were detected in radiological imaging test 2 months after the completion of radiotherapy, and we carefully followed up without any treatment considering the patient's tolerability for further procedures. Six months after recurrence, she experienced cytoreduction in the metastatic lesions confirmed through imaging findings, which was believed to be an abscopal effect, and maintained this shrinking state for 15 months. Herein, we describe this pure abscopal effect from the perspective of imaging, pathological and molecular findings, and therapeutic strategies.

    DOI： 10.1016/j.radcr.2023.04.031

    PubMed

    researchmap

  • ADAR1 has an oncogenic function and can be a prognostic factor in cervical cancer. 国際誌

    Keiichiro Nakamura, Kunitoshi Shigeyasu, Kazuhiro Okamoto, Hirofumi Matsuoka, Hisashi Masuyama

    Scientific reports   13 ( 1 )   4720 - 4720   2023年3月

    　詳細を見る

    記述言語：英語   掲載種別：研究論文（学術雑誌）  

    Adenosine deaminase acting on RNA 1 (ADAR1), a recently described epigenetic modifier, is believed to play a critical oncogenic role in human cancers. However, its functional role and clinical significance in cervical cancer (CC) remain unclear. ADAR1 knockdown was performed to investigate its oncogenic functions in SiHa (HPV16), HeLa (HPV18), and Yumoto (non-HPV) CC cell lines. Cytoplasmic and nuclear ADAR1 expression were examined to clarify their correlation with clinicopathological parameters and prognosis in patients with CC. This resulted in increased apoptosis and necroptosis in HPV16 -type SiHa, HPV18-type HeLa, and non-HPV-type Yumoto CC cell lines. Progression-free survival (PFS) rates of patients exhibiting high cytoplasmic and nuclear ADAR1 expression were poorer than those in the other groups (P = 0.016). Multivariate analysis indicated that the combination of higher cytoplasmic and nuclear ADAR1 expression was an independent predictor of prognosis in patients with CC (P = 0.017). ADAR1 could be a potential therapeutic target for HPV-positive or HPV-negative CC. The combination of cytoplasmic and nuclear ADAR1 comprises a better prognostic factor for CC.

    DOI： 10.1038/s41598-023-30452-y

    PubMed

    researchmap

  • Molecular Characteristics of Metastatic Lesions Have Superior Prognostic Impact on Endometrial Cancer. 国際誌

    Kazuhiro Okamoto, Keiichiro Nakamura, Junko Haraga, Hisashi Masuyama

    Anticancer research   42 ( 9 )   4535 - 4543   2022年9月

    　詳細を見る

    記述言語：英語   掲載種別：研究論文（学術雑誌）  

    BACKGROUND/AIM: In endometrial cancer (EC), lymph node (LN) metastasis significantly impacts prognosis. Thus far, no studies have reported the molecular genetics of each metastatic lesion. This study aimed to investigate the molecular characteristics of primary and metastatic LNs and their association with clinical outcomes. PATIENTS AND METHODS: The clinicopathological and molecular characteristics of 33 patients with EC with regional LN metastasis (FIGO stage IIIC) were investigated; we evaluated the mutational status of p53 and DNA mismatch repair (MMR) proteins in the primary lesion, all the positive LNs (102 lesions), mutational variation between primary and paired metastatic lesions, inter-lesion heterogeneity, and their association with clinical outcomes. RESULTS: Immunohistochemically, 12 patients (36.4%) displayed aberrant p53 expression in metastatic lesions, and a concordant rate of 93.4% was observed between primary and metastatic lesions. Inter-lesion heterogeneity was observed in 20 cases (60.6%). In Kaplan-Meier analysis, patients with aberrant p53 expression in metastatic LNs exhibited worse progression-free survival (PFS) than those with wild-type p53 expression (p=0.008). Wild-type p53 expression in primary lesion with inter-lesion heterogeneity had a significantly worse PFS (p=0.049) than those without heterogeneity. In the Cox univariate analysis, p53 expression in metastatic LNs was significantly associated with recurrence (p=0.013). Genetic diversity between primary and metastatic lesions and among metastases was validated by evaluating the p53 and MMR proteins using immunohistochemistry analysis. CONCLUSION: The molecular characteristics of metastatic lesions in addition to those of primary lesions could provide beneficial prognostic information in patients with EC with regional LN metastasis.

    DOI： 10.21873/anticanres.15956

    PubMed

    researchmap

  • ADAR1 and AZIN1 RNA editing function as an oncogene and contributes to immortalization in endometrial cancer. 国際誌

    Keiichiro Nakamura, Kunitoshi Shigeyasu, Kazuhiro Okamoto, Hirofumi Matsuoka, Hisashi Masuyama

    Gynecologic oncology   166 ( 2 )   326 - 333   2022年8月

    　詳細を見る

    記述言語：英語   掲載種別：研究論文（学術雑誌）  

    OBJECTIVE: Adenosine-to-inosine (A-to-I) RNA editing is a recently described epigenetic modification, which is believed to constitute a key oncogenic mechanism in human cancers. However, its functional role and clinical significance in endometrial cancer (EC) remain unclear. METHODS: Adenosine Deaminase family Acting on RNA1 (ADAR1) expression and Antizyme inhibitor 1 (AZIN1) RNA editing were examined to clarify the correlation with clinicopathological parameters and prognosis in EC patients. The biological functions and inhibitory effects of ADAR1 knockdown were investigated in JHUCS-1 and TU-ECS-1 EC cell lines. RESULTS: ADAR1 showed significant association with worse histology (P = 0.006), and lymph vascular space involvement (P = 0.049) in EC. The level of AZIN1 RNA editing was also significantly associated with worse histology (P = 0.012). ADAR1 expression was significantly correlated with AZIN1 RNA editing level (R = 0.729, R2 = 0.547, P < 0.001). Multivariate analysis indicated that higher ADAR1 expression along with AZIN1 RNA editing is an independent predictor of prognosis in EC patients (P = 0.015). Knockdown of ADAR1 led to increased MDA-5, RIG-I, PKR, and IRF-7 expression, which in turn resulted in increased levels of Bak and apoptosis in EC cells. CONCLUSIONS: High ADAR1 expression along with AZIN1 RNA editing could be a predictor of worse prognosis in EC. ADAR1 could be a potential therapeutic target in EC patients.

    DOI： 10.1016/j.ygyno.2022.05.026

    PubMed

    researchmap

  • 当院で施行した婦人科癌のがんゲノム医療の現況と課題

    依田 尚之, 小川 千加子, 入江 恭平, 岡本 和浩, 松岡 敬典, 久保 光太郎, 中村 圭一郎, 長尾 昌二, 増山 寿, 平沢 晃

    日本婦人科腫瘍学会学術講演会プログラム・抄録集   64回   205 - 205   2022年7月

    　詳細を見る

    記述言語：日本語   出版者・発行元：(公社)日本婦人科腫瘍学会  

    researchmap

  • The Combination of D-dimer and Glasgow Prognostic Score Can Be Useful in Predicting VTE in Patients with Stage IIIC and IVA Ovarian Cancer.

    Kotaro Kubo, Keiichiro Nakamura, Kazuhiro Okamoto, Hirofumi Matsuoka, Naoyuki Ida, Tomoko Haruma, Chikako Ogawa, Hisashi Masuyama

    Acta medica Okayama   76 ( 2 )   129 - 135   2022年4月

    　詳細を見る

    記述言語：英語   掲載種別：研究論文（学術雑誌）  

    Cancer patients have increased risk of venous thromboembolism (VTE) that must be assessed before treatment. This study aimed to determine effective VTE biomarkers in gynecologic cancer (GC). We investigated the correlation between D-dimer levels, Khorana risk score (KRS), Glasgow prognostic score (GPS), and VTE in 1499 GC patients (583 cervical cancer (CC), 621 endometrial cancer (EC), and 295 ovarian cancer (OC) patients) treated at our institution between January 2008 and December 2019. χ2 and Mann-Whitney U-tests were used to determine statistical significance. We used receiver operating characteristic-curve analysis to evaluate the discriminatory ability of each parameter. D-dimer levels were significantly correlated with KRS and GPS in patients with GC. VTE was diagnosed in 11 CC (1.9%), 27 EC (4.3%), and 39 OC patients (13.2%). Optimal D-dimer cut-off values for VTE were 3.1, 3.2, and 3.9 μg/ml in CC, EC and OC patients, respectively. D-dimer could significantly predict VTE in all GC patients. Furthermore, D-dimer combined with GPS was more accurate in predicting VTE than other VTE biomarkers in stage IIIC and IVA OC (AUC: 0.846; p<0.001). This study demonstrates that combined D-dimer and GPS are useful in predicting VTE in patients with OC.

    DOI： 10.18926/AMO/63406

    PubMed

    researchmap

  • プラチナ抵抗性再発卵巣癌に対してプラチナ製剤を再投与し奏功した2症例

    小川 麻理子, 依田 尚之, 入江 恭平, 岡本 和浩, 松岡 敬典, 小川 千加子, 中村 圭一郎, 長尾 昌二, 増山 寿

    日本産科婦人科学会雑誌   74 ( 臨増 )   S - 324   2022年2月

    　詳細を見る

    記述言語：日本語   出版者・発行元：(公社)日本産科婦人科学会  

    researchmap

  • プラチナ抵抗性再発卵巣癌に対して非プラチナ製剤を投与した後,プラチナ製剤を再投与した症例の検討

    依田 尚之, 入江 恭平, 岡本 和浩, 松岡 敬典, 小川 千加子, 中村 圭一郎, 長尾 昌二, 増山 寿

    日本産科婦人科学会雑誌   74 ( 臨増 )   S - 503   2022年2月

    　詳細を見る

    記述言語：日本語   出版者・発行元：(公社)日本産科婦人科学会  

    researchmap

  • 再発卵巣癌に対するPARP阻害剤維持療法の施行状況と安全性の検討

    松岡 敬典, 中村 圭一郎, 入江 恭平, 岡本 和浩, 依田 尚之, 小川 千加子, 長尾 昌二, 増山 寿

    日本産科婦人科学会雑誌   74 ( 臨増 )   S - 496   2022年2月

    　詳細を見る

    記述言語：日本語   出版者・発行元：(公社)日本産科婦人科学会  

    researchmap

  • MRI検査・FDG-PET検査で悪性を疑う所見を認め,術前に悪性外陰腫瘍と考えた結節性筋膜炎の一例

    西田 康平, 岡本 和浩, 入江 恭平, 松岡 敬典, 依田 尚之, 小川 千加子, 中村 圭一郎, 長尾 昌二, 増山 寿

    日本産科婦人科学会雑誌   74 ( 臨増 )   S - 343   2022年2月

    　詳細を見る

    記述言語：日本語   出版者・発行元：(公社)日本産科婦人科学会  

    researchmap

  • 当院で免疫チェックポイント阻害剤を投与した6症例

    長谷井 稜子, 松岡 敬典, 入江 恭平, 岡本 和浩, 依田 尚之, 小川 千加子, 中村 圭一郎, 増山 寿

    日本産科婦人科学会雑誌   74 ( 臨増 )   S - 301   2022年2月

    　詳細を見る

    記述言語：日本語   出版者・発行元：(公社)日本産科婦人科学会  

    researchmap

  • 肥満を伴う子宮体癌患者に対して腹腔鏡下手術を施行した2症例の検討

    篠崎 真里奈, 久保 光太郎, 栗山 千晶, 依田 尚之, 岡本 和浩, 松岡 敬典, 小川 千加子, 中村 圭一郎, 増山 寿

    日本産科婦人科学会雑誌   74 ( 臨増 )   S - 475   2022年2月

    　詳細を見る

    記述言語：日本語   出版者・発行元：(公社)日本産科婦人科学会  

    researchmap

  • 当院における子宮体がんの遺伝子パネル検査の検討

    岡本 和浩, 小川 千加子, 松岡 敬典, 依田 尚之, 久保 光太郎, 春間 朋子, 中村 圭一郎, 平沢 晃, 増山 寿

    日本婦人科腫瘍学会学術講演会プログラム・抄録集   63回   214 - 214   2021年7月

    　詳細を見る

    記述言語：日本語   出版者・発行元：(公社)日本婦人科腫瘍学会  

    researchmap

  • 当科における子宮頸癌に対するがんパネル検査の現況

    松岡 敬典, 小川 千加子, 岡本 和浩, 依田 尚之, 久保 光太郎, 春間 朋子, 中村 圭一郎, 平沢 晃, 増山 寿

    日本婦人科腫瘍学会学術講演会プログラム・抄録集   63回   337 - 337   2021年7月

    　詳細を見る

    記述言語：日本語   出版者・発行元：(公社)日本婦人科腫瘍学会  

    researchmap

  • 当院で施行した卵巣がんのがんゲノム医療の現況

    依田 尚之, 小川 千加子, 岡本 和浩, 松岡 敬典, 久保 光太郎, 春間 朋子, 中村 圭一郎, 増山 寿, 平沢 晃

    日本婦人科腫瘍学会学術講演会プログラム・抄録集   63回   209 - 209   2021年7月

    　詳細を見る

    記述言語：日本語   出版者・発行元：(公社)日本婦人科腫瘍学会  

    researchmap

  • 卵巣癌易罹患性に関する遺伝学的背景を持つ卵巣子宮内膜症性嚢胞から癌化をきたした2症例

    小川 千加子, 依田 尚之, 松岡 敬典, 入江 恭平, 岡本 和浩, 春間 朋子, 中村 圭一郎, 平沢 晃, 増山 寿

    日本婦人科腫瘍学会学術講演会プログラム・抄録集   63回   245 - 245   2021年7月

    　詳細を見る

    記述言語：日本語   出版者・発行元：(公社)日本婦人科腫瘍学会  

    researchmap

  • 高エストロゲン血症を伴う卵巣偽粘液腫の一例

    川口 優里香, 小川 千加子, 松岡 敬典, 岡本 和浩, 依田 尚之, 春間 朋子, 中村 圭一郎, 増山 寿

    日本産科婦人科学会雑誌   73 ( 臨増 )   S - 331   2021年3月

    　詳細を見る

    記述言語：日本語   出版者・発行元：(公社)日本産科婦人科学会  

    researchmap

  • The presence of chronic diseases contributes to the occurrence risk factors for gynecological cancers in Japan. 国際誌

    Kazuhiro Okamoto, Keiichiro Nakamura, Hirofumi Matsuoka, Yuko Matsubara, Junko Haraga, Chikako Ogawa, Hisashi Masuyama

    Molecular and clinical oncology   12 ( 4 )   336 - 342   2020年4月

    　詳細を見る

    記述言語：英語   掲載種別：研究論文（学術雑誌）  

    The aim of the present study was to determine whether chronic diseases (CD), such as hypertension, diabetes mellitus, dyslipidemia, heart diseases and cerebrovascular diseases, are occurrence risk factors and affect the survival of patients with gynecological cancers (GC). The correlations between CD and the characteristics and survival of 1,590 GC patients [685 with cervical cancer (CC), 613 with endometrial cancer (EM) and 292 with ovarian cancer (OV)] were investigated in the present study. Of the CD patients, 189 had CC (27.6%), 265 had EM (43.2%) and 72 had OV (24.7%). The incidence of CD increased with age in GC patients. The number of CD patients aged ≥70 years, was 8.6-fold higher in the CC group, 3.0-fold higher in the EM group, and 9.6-fold higher in the OV group compared with those aged <50 years. CD and excess body weight were associated with GC regardless of patient age. However, there was no correlation between CD and survival at any age in GC patients. These findings indicate that CD contribute to >24% of the occurrence risk factors in GC patients in Japan.

    DOI： 10.3892/mco.2020.1989

    PubMed

    researchmap

  • A Case of Spontaneous Tumor Lysis Syndrome in a Patient with Ovarian Cancer. 国際誌

    Kazuhiro Okamoto, Toshifumi Kinoshita, Miyuki Shimizu, Isoji Okura, Akinori Kawada, Koichi Mizobuchi, Midori Ando

    Case reports in obstetrics and gynecology   2015   461870 - 461870   2015年

    　詳細を見る

    記述言語：英語   掲載種別：研究論文（学術雑誌）  

    Tumor lysis syndrome (TLS) is a potentially life-threating complication of tumors or chemotherapy treatment. TLS commonly occurs in hematological malignancies, but it is very rare in patients with a solid tumor. In cases of solid tumors, TLS usually occurs spontaneously and after the initiation of anticancer therapy, and it has a high mortality rate. We present the novel case of a 62-year-old woman with an ovarian tumor who spontaneously developed TLS. Surgical reduction of the tumor mass vastly improved her condition. She showed no sign of tumor recurrence 8 months after treatment. As TLS is life-threatening, successful treatments must be seriously considered.

    DOI： 10.1155/2015/461870

    PubMed

    researchmap

  • A case of cardiac metastasis from uterine cervical carcinoma. 国際誌

    Kazuhiro Okamoto, Tomoyuki Kusumoto, Noriko Seki, Keiichiro Nakamura, Yuji Hiramatsu

    Case reports in obstetrics and gynecology   2015   703424 - 703424   2015年

    　詳細を見る

    記述言語：英語   掲載種別：研究論文（学術雑誌）  

    Cases of cardiac metastasis from uterine cervical carcinoma are rare. While they are occasionally found on autopsy, antemortem recognition is extremely rare. We confirmed a case of cardiac metastasis from cervical carcinoma antemortem, because we observed a decrease in platelet count during the course of treatment. The patient was a 27-year-old woman diagnosed with stage Ib1 uterine cervical carcinoma. Radical hysterectomy with pelvic lymphadenectomy was performed. Para-aortic lymph node metastasis was detected on positron emission tomography/computed tomography (PET-CT). Adjuvant chemotherapy was started, and most of the metastatic lesions disappeared. Pelvic lymph node recurrence was suspected on PET-CT during continued chemotherapy; therefore, treatment was shifted to radiation therapy. Tumor shrinkage was recognized, and the initial therapy was completed. A noticeable decrease in platelet count was recognized seven months after treatment. Multidetector CT was performed, and an intracardiac tumor was detected. The patient did not desire any further treatment. She died three weeks after the intracardiac tumor was confirmed. Few previous autopsy studies have reported cardiac metastasis from cervical carcinoma. Thus, it is necessary to consider the possibility of cardiac metastasis for patients diagnosed with terminal cervical carcinoma.

    DOI： 10.1155/2015/703424

    PubMed

    researchmap

▼全件表示

MISC

▼全件表示

共同研究・競争的資金等の研究

  • 子宮体癌におけるRNA編集解明と新規治療戦略の探索

    研究課題/領域番号：22K09619  2022年04月 - 2025年03月

    日本学術振興会  科学研究費助成事業  基盤研究(C)

    中村 圭一郎, 増山 寿, 小川 千加子, 松岡 敬典, 岡本 和浩, 依田 尚之

    　 詳細を見る

    配分額：4160000円 （ 直接経費：3200000円 、 間接経費：960000円 ）

    子宮体癌はTCGAによる総合的ゲノム解析結果から4つのサブタイプに分類され，我々も遺伝子解析を鋭意遂行し，遺伝子変異の照合を行い，ゲノム解析を推進してきた。しかしゲノム変異情報だけによるPrecision Medicineには限界があり，より細やかなPersonalized Medicineへ繋ぐためにはゲノム変異だけでない新規治療戦略が必要である。癌細胞は「RNA 編集」といわれるRNA 転写後塩基の修飾が行われ，タンパクの構造変化やマイクロRNAとの親和性の変化を引き起こし，癌の悪性度を増すことが報告されているが，子宮体癌におけるRNA 編集の意義についてはいまだ未知のままである。そこで子宮体癌におけるRNA編集の意義を解析するとともにこれをターゲットとした新しい癌治療戦略の確立を目指している。現在，RNA 編集の解析が注目され始めてきているが，しかし婦人科領域でのADAR1の詳細な検討は少なく，子宮体癌研究は詳細な検討は，いまだ数例しか報告されていない。そこで本研究は，子宮体癌のRNA編集意義を解析するとともに，これをターゲットとした新しい癌治療戦略の確立を目指すことを目的にした。我々は今まで採取したヒト検体を用いて，ADAR1発現を確認し，他の組織と比較し，癌肉腫に高発現しており、予後においてもADAR1高発現は低発現よりも予後不良であることが認められた。令和5年度は、当初予定していたTCGAから発表された4つのサブタイプとの相関関係や子宮体癌におけるADAR1のメカニズム解明を行っうため，免疫染色法やサンガー法を用いて，子宮体癌とRNA編集関係を明確にするために研究を遂行している。

    researchmap